# Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

> **NCT00761631** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1200 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **BIOLOGICAL:** 13 valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT00761631
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2013-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761631, "Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00761631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*